

## Purified anti-mouse CD8a Antibody

<b>Catalog# / Size</b>	100701 / 50 µg 100702 / 500 µg
<b>Clone</b>	53-6.7
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T8, Lyt2, Ly-2
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography.
<b>Concentration</b>	0.5 mg/mL
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C.
<b>Application</b>	<a href="#">FC - Quality tested</a> <a href="#">CyTOF®, IHC-F - Verified</a> <a href="#">IP - Reported in the literature, not verified in house</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µL volume. For immunohistochemistry on frozen tissue sections, the suggested use of this reagent is 5.0 - 10 µg per mL. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Application Notes</b>	Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes <sup>3</sup> . The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a <sup>+</sup> cells. Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>1,3</sup> , <i>in vivo</i> and <i>in vitro</i> cell depletion <sup>2,10,15</sup> , inhibition of CD8 T cell proliferation <sup>3</sup> , blocking of cytotoxicity <sup>3,4</sup> , immunohistochemical staining <sup>5,6</sup> of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX) <sup>29,30</sup> . Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or <i>in vivo</i> studies (Cat No. 100746).
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Ledbetter JA, <i>et al.</i> 1979. <i>Immunol. Rev.</i> 47:63. (IHC, IP)</li> <li>2. Hathcock KS. 1991. <i>Current Protocols in Immunology</i>. 3.4.1. (Deplete)</li> <li>3. Takahashi K, <i>et al.</i> 1992. <i>P. Natl. Acad. Sci. USA</i> 89:5557. (Block, IP)</li> <li>4. Ledbetter JA, <i>et al.</i> 1981. <i>J. Exp. Med.</i> 153:1503. (Block)</li> <li>5. Hata H, <i>et al.</i> 2004. <i>J. Clin. Invest.</i> 114:582. (IHC)</li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

6. Fan WY, *et al.* 2001. *Exp. Biol. Med.* 226:1045. (IHC)
7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
8. Kamimura D, *et al.* 2006. *J. Immunol.* 177:306.
9. Bouwer HGA, *et al.* 2006. *P. Natl. Acad. Sci. USA* 103:5102. (FC, Deplete)
10. Kao C, *et al.* 2005. *Int. Immunol.* 17:1607. [PubMed](#)
11. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309. (FC) [PubMed](#)
12. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
13. Lee CH, *et al.* 2009. *Clin. Cancer Res.* [PubMed](#)
14. Geiben-Lynn R, *et al.* 2008. *Blood* 112:4585. (Deplete) [PubMed](#)
15. Kingeter LM, *et al.* 2008. *J. Immunol.* 181:6244. [PubMed](#)
16. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
17. Andrews DM, *et al.* 2008. *J. Virol.* 82:4931. [PubMed](#)
18. Britschqui MR, *et al.* 2008. *J. Immunol.* 181:7681. [PubMed](#)
19. Kenna TJ, *et al.* 2008. *Blood* 111:2091. [PubMed](#)
20. Jordan JM, *et al.* 2008. *Infect. Immun.* 76:3717. [PubMed](#)
21. Todd DJ, *et al.* 2009. *J. Exp. Med.* 206:2151. [PubMed](#)
22. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
23. Medyouf H, *et al.* 2010. *Blood* 115:1175. [PubMed](#)
24. Riedl P, *et al.* 2009. *J. Immunol.* 183:370. [PubMed](#)
25. Apte SH, *et al.* 2010. *J. Immunol.* 185:998. [PubMed](#)
26. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
27. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
28. Cui L, *et al.* 2015. *J Control Release.* 206:220. [PubMed](#)
29. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
30. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Dallari S, *et al.* 2017. *Nat Commun.* 8:14830. [PubMed](#)
2. Toubai T, *et al.* 2017. *Blood Adv.* 1.095138889. [PubMed](#)
3. Arnold IC, *et al.* 2019. *PLoS Pathog.* 15:e1007866. [PubMed](#)
4. Kobayashi A, *et al.* 2021. *Front Immunol.* 12:650856. [PubMed](#)
5. Tersteegen A, *et al.* 2021. *Infect Immun.* 89:. [PubMed](#)
6. Kao C, *et al.* 2005. *Int Immunol.* 1.824305556. [PubMed](#)
7. Krovi SH, *et al.* 2019. *Proc Natl Acad Sci U S A.* 116:22252. [PubMed](#)
8. Thelin MA, *et al.* 2017. *Diabetes.* 66:2220. [PubMed](#)
9. Thi VAD, *et al.* 2019. *Mol Cells.* 42:869. [PubMed](#)
10. Asthagiri Arunkumar G, *et al.* 2019. *Vaccine.* 37:5567. [PubMed](#)
11. Burrello C, *et al.* 2018. *Front Med (Lausanne).* 5:21. [PubMed](#)
12. Chartrand K, *et al.* 2018. *Front Immunol.* 1.642361111. [PubMed](#)
13. Bajaña S, *et al.* 2021. *Front Immunol.* 11:577718. [PubMed](#)
14. Murata A, *et al.* 2020. *Front Immunol.* 11:775. [PubMed](#)
15. Wang C, *et al.* 2020. *Oncoimmunology.* 9:1809947. [PubMed](#)
16. Ma J, *et al.* 2020. *Adv Sci (Weinh).* 7:2000609. [PubMed](#)
17. Rubio-Patiño C *et al.* 2018. *Cell metabolism.* 27(4):828-842. [PubMed](#)
18. Rieck M, *et al.* 2017. *Eur J Immunol.* 47:677. [PubMed](#)
19. Goel S, *et al.* 2017. *Nature.* 548:471. [PubMed](#)
20. Bradford BM, *et al.* 2018. *Parasite Immunol.* 40:e12566. [PubMed](#)
21. Field CS, *et al.* 2018. *Oncoimmunology.* 7:e1376154. [PubMed](#)
22. Wang W, *et al.* 2018. *Cancer Cell.* 34:757. [PubMed](#)
23. Boldison J, *et al.* 2020. *Cell Mol Immunol.* 17:843. [PubMed](#)
24. Prado C, *et al.* 2021. *J Neuroinflammation.* 18:292. [PubMed](#)
25. Carpenter SM, *et al.* 2017. *PLoS Pathog.* 13:e1006704. [PubMed](#)
26. Gao J, *et al.* 2017. *Oncol Lett.* 14:2954. [PubMed](#)
27. Haque M, *et al.* 2021. *Viruses.* 13:. [PubMed](#)
28. Mayer JU, *et al.* 2020. *Front Immunol.* 11:592325. [PubMed](#)
29. Tian K, *et al.* 2021. *J Immunol Res.* 2021:6297332. [PubMed](#)
30. Nguyen N, *et al.* 2022. *iScience.* 25:103679. [PubMed](#)
31. Hirano J, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118:. [PubMed](#)
32. Draganov D, *et al.* 2021. *NPJ Breast Cancer.* 7:22. [PubMed](#)
33. Rossi DC, *et al.* 2021. *J Clin Invest.* 131:. [PubMed](#)
34. Zhou AC, *et al.* 2017. *Front Immunol.* 1.136111111. [PubMed](#)
35. Ma C, *et al.* 2018. *Science.* 360:eaan5931. [PubMed](#)
36. Kaplanov I, *et al.* 2019. *Proc Natl Acad Sci U S A.* 116:1361. [PubMed](#)
37. Niss Arfelt K, *et al.* 2017. *Blood.* 129:866. [PubMed](#)
38. Joseph R, *et al.* 2021. *Br J Cancer.* 125:176. [PubMed](#)
39. Willmsky G, *et al.* 2021. *Elife.* 10:. [PubMed](#)
40. Tian D, *et al.* 2020. *FASEB J.* 34:3367. [PubMed](#)
41. Stefanescu C, *et al.* 2021. *Front Oncol.* 11:765151. [PubMed](#)
42. McLeod RL, *et al.* 2018. *Oncotarget.* 9:34459. [PubMed](#)
43. Bartsch YC, *et al.* 2018. *Front Immunol.* 1.196527778. [PubMed](#)
44. Morabito KM, *et al.* 2017. *Mucosal Immunol.* 0.795138889. [PubMed](#)
45. Recino A, *et al.* 2019. *Gene Ther.* 26:40. [PubMed](#)
46. Jackson JW, *et al.* 2021. *Mol Ther Oncolytics.* 22:444. [PubMed](#)
47. Mayer KA, *et al.* 2021. *FASEB J.* 35:e21217. [PubMed](#)
48. Peng V, *et al.* 2020. *J Biol Chem.* 295:14866. [PubMed](#)
49. Yang M, *et al.* 2020. *Oncoimmunology.* 9:1708064. [PubMed](#)
50. Hiramatsu-Asano S, *et al.* 2021. *Front Immunol.* 11:616141. [PubMed](#)
51. Doorduijn EM, *et al.* 2018. *Front Immunol.* 0.416666667. [PubMed](#)
52. Sun H, *et al.* 2018. *J Cell Biol.* 217:1453. [PubMed](#)

53. Chen S, *et al.* 2018. Immunohorizons. 0.345138889. [PubMed](#)
54. Guo Y, *et al.* 2008. Blood. 112:480. [PubMed](#)
55. Wang N, *et al.* 2021. Mol Ther Oncolytics. 20:71. [PubMed](#)
56. Suzuki Y, *et al.* 2021. FEBS Open Bio. 11:2619. [PubMed](#)
57. Yan J, *et al.* 2020. Cancer Immunol Res. 8:356. [PubMed](#)
58. Chen L, *et al.* 2020. Front Immunol. 11:584458. [PubMed](#)
59. Bertino P, *et al.* 2019. Oncoimmunology. 8:1601482. [PubMed](#)
60. Seelige R, *et al.* 2018. Sci Rep. 8:13670. [PubMed](#)
61. Yang SH, *et al.* 2017. Front Immunol. 8:1192. [PubMed](#)
62. Zhao L, *et al.* 2018. Nat Med. 24:1536. [PubMed](#)
63. Hiratsuka S, *et al.* 2018. EMBO Mol Med. 10:e8643. [PubMed](#)
64. Stacey MA, *et al.* 2017. J Clin Invest. 127:1463. [PubMed](#)
65. Sharma M, *et al.* 2020. Nat Commun. 11:661. [PubMed](#)
66. Mori H, *et al.* 2015. Toxicol Pathol. 43: 883-889. [PubMed](#)
67. Gozgit JM, *et al.* 2021. Cancer Cell. .: [PubMed](#)
68. Lasso P, *et al.* 2020. Front Immunol. 584959:11. [PubMed](#)
69. Furukawa K, *et al.* 2017. PLoS One. 10.1371/journal.pone.0184901. [PubMed](#)
70. Zhao F, *et al.* 2018. Cancer Immunol Res. 1.263194444. [PubMed](#)
71. Gartlan KH, *et al.* 2019. Blood Adv. 2.110416667. [PubMed](#)
72. Abboud G, *et al.* 2018. Front Immunol. 9:1973. [PubMed](#)
73. Sharba S, *et al.* 2019. Virulence. 10:97. [PubMed](#)
74. Xie D, *et al.* 2020. Eur J Immunol. 50:1729. [PubMed](#)
75. Liu H, *et al.* 2020. J Immunol. 205:1207. [PubMed](#)
76. Brown IK, *et al.* 2021. PLoS Pathog. 17:e1009602. [PubMed](#)
77. Zhong X, *et al.* 2020. Proc Natl Acad Sci U S A. 8563:117. [PubMed](#)
78. Zareie P, *et al.* 2017. J Neuroinflammation. 0.630555556. [PubMed](#)
79. Kim SJ, *et al.* 2017. Nat Immunol. 18:1016. [PubMed](#)
80. Tsubaki T, *et al.* 2018. Oncotarget. 9:11209. [PubMed](#)
81. Hoves S, *et al.* 2018. J Exp Med. 215:859. [PubMed](#)
82. Hsiao CC, *et al.* 2021. Cells. 10: [PubMed](#)
83. Dooley K, *et al.* 2021. Mol Ther. 29:1729. [PubMed](#)
84. Dai Z, *et al.* 2021. JCI Insight. 6: [PubMed](#)
85. Sprouse ML, *et al.* 2018. JCI Insight. 3:e97322. [PubMed](#)
86. Lee JY, *et al.* 2018. Front Immunol. 0.678472222. [PubMed](#)
87. Sheppard S, *et al.* 2018. Front Immunol. 1.630555556. [PubMed](#)
88. Sharabi A, *et al.* 2019. JCI Insight. 4:e126294. [PubMed](#)
89. Chihara N, *et al.* 2018. Nature. 558:454. [PubMed](#)
90. Shin J, *et al.* 2018. Diabetes. 67:1068. [PubMed](#)
91. Majer O, *et al.* 2019. Nature. 575:366. [PubMed](#)
92. Tao H, *et al.* 2021. Front Immunol. 12:623280. [PubMed](#)
93. Jang SC, *et al.* 2021. Commun Biol. 4:497. [PubMed](#)
94. You X, *et al.* 2022. Front Genet. 12:790990. [PubMed](#)
95. Zelazowska MA, *et al.* 2020. Life Sci Alliance. :3. [PubMed](#)
96. Murakami R, *et al.* 2013. PLoS One. 8:73270. [PubMed](#)
97. Kenna T, *et al.* 2008. Blood. 111:2091. [PubMed](#)
98. King IL, *et al.* 2017. Mucosal Immunol. 10:1160. [PubMed](#)
99. Yates K, *et al.* 2018. Proc Natl Acad Sci U S A. 115:2162. [PubMed](#)
100. Simula L, *et al.* 2018. Cell reports. 25(11):3059-3073. [PubMed](#)
101. Oyarce K, *et al.* 2018. Front Immunol. 9:112. [PubMed](#)
102. Gilfillan CB, *et al.* 2020. Eur J Immunol. 50:505. [PubMed](#)
103. Chen HW, *et al.* 2021. Biomedicines. 9: [PubMed](#)
104. Tan CL, *et al.* 2018. Immunohorizons. 0.248611111. [PubMed](#)
105. Mensurado S, *et al.* 2018. PLoS Biol. 16:e2004990. [PubMed](#)
106. Yoon BH, *et al.* 2018. Mol Cells. 41:953. [PubMed](#)
107. Bajic D, *et al.* 2020. Mol Cancer Ther. 19:2554. [PubMed](#)
108. Ikezoe T, *et al.* 2021. Biomolecules. 11: [PubMed](#)
109. Li J, *et al.* 2021. Front Immunol. 12:710406. [PubMed](#)
110. Dionisio-Santos DA, *et al.* 2021. Front Neurosci. 15:758677. [PubMed](#)
111. Goh W, *et al.* 2020. Cell Rep. 33:108285. [PubMed](#)
112. Kakaradov B, *et al.* 2017. Nat Immunol. 18:422. [PubMed](#)
113. Kim D, *et al.* 2019. Immune Netw. 19:e32. [PubMed](#)
114. Rosenbaum M, *et al.* 2019. Nat Commun. 2.05. [PubMed](#)
115. Meyers JL, *et al.* 2018. PLoS One. 13:e0207007. [PubMed](#)
116. Kawabe T, *et al.* 2017. Sci Immunol. 2:eaam9315. [PubMed](#)
117. Seo SU, *et al.* 2021. Front Immunol. 12:697162. [PubMed](#)
118. Duncan CG, *et al.* 2018. G3 (Bethesda). 0.892361111. [PubMed](#)
119. Roussey JA, *et al.* 2017. J Immunol. 199:3535. [PubMed](#)
120. Ko S, *et al.* 2005. J Immunol. 175:3309. [PubMed](#)
121. Shissler SC, *et al.* 2020. Sci Rep. 10:8218. [PubMed](#)
122. Scortegagna M, *et al.* 2020. Nat Commun. 11:99. [PubMed](#)
123. Brownlie D, *et al.* 2021. J Immunother Cancer. 9: [PubMed](#)
124. Tsai MS, *et al.* 2021. Int J Mol Sci. 22: [PubMed](#)
125. Zhang Z, *et al.* 2020. Front Immunol. 1.844444444. [PubMed](#)
126. Brown ZJ, *et al.* 2018. Cell Death Dis. 0.805555556. [PubMed](#)
127. Stelekati E, *et al.* 2018. Cell Rep. 2.445833333. [PubMed](#)
128. Cui X, *et al.* 2017. J Immunol. 199:4066. [PubMed](#)
129. Lin Z, *et al.* 2021. Stem Cells. 39:240. [PubMed](#)
130. Amobi-McCloud A, *et al.* 2021. Front Immunol. 12:678999. [PubMed](#)
131. Sami E, *et al.* 2020. Cancer Res. 80:1102. [PubMed](#)
132. Zhang C, *et al.* 2018. Cell Res. 28:323. [PubMed](#)

133. Afzali B, *et al.* 2017. *Nat Immunol.* 18:813. [PubMed](#)
134. Lee YJ, *et al.* 2018. *Front Microbiol.* 9:83. [PubMed](#)
135. Satoh–Takayama N, *et al.* 2020. *Immunity.* 52(4):635-649. [PubMed](#)
136. Lee B, *et al.* 2019. *Front Immunol.* 0.561805556. [PubMed](#)
137. Dey P, *et al.* 2020. *Cancer Discov.* 10:608. [PubMed](#)
138. Mohrin M, *et al.* 2021. *Aging Cell.* 20:e13313. [PubMed](#)
139. Udumula MP, *et al.* 2021. *Mol Metab.* 53:101272. [PubMed](#)
140. Freed-Pastor WA, *et al.* 2021. *Cancer Cell.* .: [PubMed](#)
141. Fujimura N, *et al.* 2016. *J Vasc Surg.* 64: 46-54. [PubMed](#)
142. Englezou PC, *et al.* 2018. *Mol Ther Nucleic Acids.* 12:118. [PubMed](#)
143. Cole C, *et al.* 2018. *Nucleic Acids Res.* 46:e62. [PubMed](#)
144. Sutherland APR, *et al.* 2019. *Sci Rep.* 9:15302. [PubMed](#)
145. Yamashita M, *et al.* 2019. *Cell Stem Cell.* 25:357. [PubMed](#)
146. Pushalkar S, *et al.* 2018. *Cancer Discov.* 0.613194444. [PubMed](#)
147. Pittala S, *et al.* 2018. *Neoplasia.* 9:20222. [PubMed](#)
148. Lin J, *et al.* 2017. *Nat Commun.* . 10.1038/s41467-017-01477-5. [PubMed](#)
149. Huppé CA, *et al.* 2018. *Mucosal Immunol.* 0.536111111. [PubMed](#)
150. Kang JG, *et al.* 2020. *PLoS Negl Trop Dis.* 14:e0007813. [PubMed](#)
151. Gorgun FM, *et al.* 2021. *Front Oncol.* 11:701968. [PubMed](#)
152. Cui L, *et al.* 2015. *J Control Release.* 206:220. [PubMed](#)
153. Lee YJ, *et al.* 2018. *FASEB J.* 32:4658. [PubMed](#)
154. Atif SM, *et al.* 2019. *JCI Insight.* 4:e125494. [PubMed](#)
155. Khameneh HJ, *et al.* 2017. *J Immunol.* 198:196. [PubMed](#)
156. Zhang J, *et al.* 2019. *Onco Targets Ther.* 12:4985. [PubMed](#)
157. Genton C, *et al.* 2006. *J Immunol.* 177:2285. [PubMed](#)
158. Jordan J, *et al.* 2008. *Infect Immun.* 76:3717. [PubMed](#)
159. Cong L, *et al.* 2021. *Breast Cancer Res.* 23:51. [PubMed](#)
160. Zhang N, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118:.. [PubMed](#)
161. Hsu HP, *et al.* 2021. *J Biol Chem.* 296:100419. [PubMed](#)
162. Song M, *et al.* 2020. *Nat Commun.* 11:6298. [PubMed](#)
163. Liu H, *et al.* 2022. *Animal Model Exp Med.* 5:72. [PubMed](#)
164. Shao Y, *et al.* 2017. *Onco Targets Ther.* 10:2675. [PubMed](#)
165. Fritz Y, *et al.* 2017. *J Invest Dermatol.* 137:696. [PubMed](#)
166. Chen YQ, *et al.* 2019. *J Immunother Cancer.* 0.415277778. [PubMed](#)
167. He X, *et al.* 2017. *Cancer Biol Ther.* 0.815277778. [PubMed](#)
168. Kästele V, *et al.* 2021. *Mucosal Immunol.* 14:717. [PubMed](#)
169. Prabakaran T, *et al.* 2021. *EBioMedicine.* 66:103314. [PubMed](#)
170. Sutiwisesak R, *et al.* 2020. *PLoS Pathog.* 16:e1009000. [PubMed](#)

**RRID** AB\_312740 (BioLegend Cat. No. 100701)  
 AB\_312741 (BioLegend Cat. No. 100702)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, CD8 $\alpha$ chain, 34 kD
<b>Distribution</b>	Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
<b>Function</b>	Co-receptor for TCR
<b>Ligand/Receptor</b>	MHC class I molecule
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li> <li>2. Zamoyska R. 1994. <i>Immunity</i> 1:243.</li> <li>3. Ellmeier W, <i>et al.</i> 1999. <i>Annu. Rev. Immunol.</i> 17:523.</li> </ol>
<b>Gene ID</b>	<a href="#">12525</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)

[Immunohistochemistry Protocol for Paraffin-Embedded Sections](#)


## Other Formats

---


APC anti-mouse CD8a, Biotin anti-mouse CD8a, FITC anti-mouse CD8a, PE anti-mouse CD8a, PE/Cyanine5 anti-mouse CD8a, Purified anti-mouse CD8a, PE/Cyanine7 anti-mouse CD8a, APC/Cyanine7 anti-mouse CD8a, Alexa Fluor® 488 anti-mouse CD8a,

Alexa Fluor® 647 anti-mouse CD8a, Pacific Blue™ anti-mouse CD8a, Alexa Fluor® 700 anti-mouse CD8a, PerCP/Cyanine5.5 anti-mouse CD8a, PerCP anti-mouse CD8a, Brilliant Violet 421™ anti-mouse CD8a, Brilliant Violet 570™ anti-mouse CD8a, Brilliant Violet 650™ anti-mouse CD8a, Brilliant Violet 605™ anti-mouse CD8a, Ultra-LEAF™ Purified anti-mouse CD8a, Brilliant Violet 711™ anti-mouse CD8a, Brilliant Violet 785™ anti-mouse CD8a, Brilliant Violet 510™ anti-mouse CD8a, Purified anti-mouse CD8a (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD8a, PE/Dazzle™ 594 anti-mouse CD8a, APC/Fire™ 750 anti-mouse CD8a, GolnVivo™ Purified anti-mouse CD8a, TotalSeq™-A0002 anti-mouse CD8a, Spark Blue™ 550 anti-mouse CD8a, Spark NIR™ 685 anti-mouse CD8a, TotalSeq™-C0002 anti-mouse CD8a, TotalSeq™-B0002 anti-mouse CD8a, Spark YG™ 570 anti-mouse CD8a, PE/Fire™ 640 anti-mouse CD8a, PE/Fire™ 700 anti-mouse CD8a, Spark Blue™ 574 anti-mouse CD8a Antibody, Spark Violet™ 423 anti-mouse CD8a Antibody, Spark UV™ 387 anti-mouse CD8a


## Product Data



C57BL/6 mouse splenocytes were stained with purified CD8 (clone 53-6.7) (filled histogram) or rat IgG2a, κ isotype control (open histogram), followed by anti-rat IgG FITC.



C57BL/6 frozen mouse spleen section was fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS for 30 minutes at room temperature. Then the section was stained with 10 µg/mL of purified anti-mouse CD8a (clone 53-6.7), 10 µg/mL of Alexa Fluor® 647 anti-CD20 (green) overnight at 4°C, followed by 2.5 µg/mL of Alexa Fluor® 594 anti-rat IgG2a (clone MRG2a-83) (red) for two hours at room temperature. The image was captured by 10X objective.



Fresh, frozen mouse spleen was stained with purified CD8a clone 53-6.7 conjugated and detected with a Cy3 CODEX™ oligonucleotide duplex (red). Samples were counterstained with B220 FITC (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587